Tabassum Hatimi, MD
Family Medicine · Anderson, INNPI 1881652022
Payments from drug & device makers
Across 342 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$910
- AbbVie$720
- Lilly USA, LLC$538
- Bayer$463
- Pfizer$443
- Sanofi$240
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$2405%
- Food & beverage$5,02195%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $910 |
| AbbVie(2 entities) | 62 | $720 |
| Lilly USA, LLC | 39 | $538 |
| Bayer | 28 | $463 |
| Pfizer | 32 | $443 |
| Sanofi | 3 | $240 |
| Lundbeck LLC | 9 | $187 |
| Amgen | 11 | $179 |
| Axsome Therapeutics, Inc. | 6 | $146 |
| AstraZeneca | 10 | $136 |
| Novartis | 6 | $113 |
| Johnson & Johnson | 7 | $111 |
| Shield Therapeutics Inc | 2 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| Medtronic | 5 | $93 |
| Boehringer Ingelheim | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $85 |
| Abbott | 6 | $84 |
| Sanofi-aventis U.S. LLC | 7 | $68 |
| Exact Sciences | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Sunovion Pharmaceuticals Inc. | 4 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Tris Pharma Inc | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| GSK | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$110
How this compares
$5,271 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 420 | $158,508 |
| OzempicSemaglutide | 117 | $133,354 |
| JardianceEmpagliflozin | 110 | $85,191 |
| RexultiBrexpiprazole | 54 | $81,465 |
| LinzessLinaclotide | 86 | $54,185 |
| TrulicityDulaglutide | 34 | $53,940 |
| JanuviaSitagliptin Phosphate | 48 | $50,643 |
| MounjaroTirzepatide | 37 | $39,044 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 103 | $32,468 |
| FarxigaDapagliflozin Propanediol | 35 | $32,131 |
| MyrbetriqMirabegron | 36 | $24,566 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $22,301 |
| XareltoRivaroxaban | 29 | $20,063 |
| EntrestoSacubitril/Valsartan | 35 | $19,580 |
| VraylarCariprazine Hcl | 14 | $18,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Paxlovid | $443 | $196,679538 claims |
| Novo NordiskOzempic | $910 | $133,354117 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $89 | $102,327165 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $538 | $92,98471 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $99 | $81,46554 claims |
| AbbVieLinzess, Vraylar, Restasis | $720 | $77,840114 claims |
| GSKAnoro Ellipta, Breo Ellipta, Shingrix | $12 | $47,837128 claims |
| AstraZenecaFarxiga | $136 | $32,13135 claims |
| Johnson & JohnsonXarelto | $111 | $20,06329 claims |
| NovartisEntresto | $113 | $19,58035 claims |
| Sanofi-aventis U.S. LLCAvapro, Lantus | $68 | $12,63489 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Anderson
- Sam ShaverAnderson$23K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.